Vanguard Capital Management’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
Other funds holding ADMA
Vanguard Capital Management's ADMA Position: Q3 2026 in Review
Vanguard Capital Management reduced its ADMA Biologics (ADMA) stake by 6.3% in Q3 2026, selling an estimated $5.88M and leaving 9,468,196 shares worth $95M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.
Vanguard Capital Management first reported a position in ADMA in Q1 2026 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.
- Vanguard Capital Management held 9,468,196 shares of ADMA Biologics worth $95M as of Q3 2026.
- Vanguard Capital Management sold 635,613 ADMA Biologics shares in Q3 2026, an estimated $5.88M.
- ADMA Biologics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1551 holding.
- Vanguard Capital Management first reported a position in ADMA Biologics in Q1 2026 and has held it in 3 quarters since.
- 327 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.